Sunday 18 October 2026
Export IRD’s income statement to Excel — free account
Opus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.81
0.24
−5.93%
Follow IRD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.96 | 8.81 | 32.99 | 39.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.93) | (12.72) | (31.06) | (32.84) | |
P/B ratio |
19.53 | 8.15 | 0.00 | 0.00 | |
Price to Tangible BV |
19.53 | 8.15 | 0.00 | 0.00 | |
EV/Sales |
5.95 | 5.72 | 28.10 | 34.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.65) | (2.30) | (8.64) | (8.33) | |
EV/FCF |
(2.53) | (2.21) | (8.30) | (8.02) | |
Quick Ratio |
1.16 | 6.05 | 6.60 | 11.82 | |
Current Ratio |
1.23 | 6.43 | 7.13 | 12.19 | |
Net Debt/EBITDA |
3.58 | 3.94 | 4.18 | 3.27 | |
Debt/Assets |
2.96% | 0.00% | 0.00% | 37.57% | |
Debt/Equity |
0.18 | 0.00 | 0.00 | (2.69) | |
Asset Turnover |
0.38 | 0.33 | 0.21 | 0.15 | |
Operating CF/Net income |
0.35 | 0.60 | 0.19 | 1.48 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(122.22) | (187.75) | (208.17) | — | |
Research and Development Expense of Revenue |
208.15% | 269.81% | 490.36% | 1,484.37% | |
Selling, General and Administrative Expense of Revenue |
161.77% | 126.52% | 275.57% | 798.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
26.50% | 20.03% | 67.87% | 186.36% | |
Graham Net Nets |
0.05 | 0.12 | (0.12) | (0.03) | |
Graham Number |
0.00 | 0.00 | 3.97 | 1.99 | |
Earnings Yield |
(113.94%) | (40.80%) | (29.23%) | (31.39%) | |
Free Cash Flow Yield |
(29.55%) | (29.46%) | (10.26%) | (10.77%) | |
Revenue per Share |
0.04 | 0.06 | 0.02 | 0.01 | |
Operating CF per Share |
(0.09) | (0.16) | (0.15) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.16) | (0.15) | (0.13) | |
Cash per Share |
0.44 | 0.72 | 0.69 | 0.93 | |
Shareholders Equity per Share |
0.08 | 0.25 | (0.53) | (0.14) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.08 | 0.25 | (0.53) | (0.14) | |
Free Cash Flow |
(6.16) | (9.83) | (12.73) | (11.95) | |
Working Capital |
6.82 | 42.26 | 57.26 | 85.09 | |
Net Current Asset Value |
5.76 | 15.15 | (46.02) | (13.26) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.39 | 2.78 | 2.41 | 2.22 | |
Average Payables |
1.62 | 3.22 | 3.43 | 1.67 | |
Average Assets |
38.26 | 43.55 | 57.48 | 65.82 | |
Average Common Equity |
20.13 | 11.04 | (20.38) | 2.24 |
Columns are period end dates